PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Network Meta-Analysis Ranks 21 Antidepressants for Acute Depression

antidepressantsmajor depressive disordernetwork meta-analysisSSRIsescitalopramsertralineamitriptylineagomelatinevortioxetinecomparative efficacypsychopharmacology Psychiatry / Psychopharmacology

Background Information

Antidepressants show varied efficacy and acceptability for major depressive disorder.

This study reviews the comparative efficacy and acceptability of 21 antidepressants for treating major depressive disorder in adults, helping guide evidence-based treatment decisions. All antidepressants were more effective than placebo; agomelatine and fluoxetine showed higher acceptability with fewer discontinuations. The findings highlight differences in efficacy and acceptability among antidepressants, providing valuable insights for prescribing decisions in major depressive disorder. Antidepressants vary significantly in efficacy and acceptability, informing personalized treatment in major depressive disorder.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR

Citation: Cipriani A, Furukawa TA, Salanti G, et al. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2026;24(2):252-262. doi:10.1176/appi.focus.26024115

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.